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Abstract 
Objective 
To evaluate the efficacy of trimethoprim- sulfamethoxazole and oral prednisolone in the 
treatment of ocular toxoplasmosis with zone-1 posterior pole and peri-papillary lesions. 
Methods 
Retrospective evaluation of records of patients in our tertiary care referral hospitals. 
  Results 
  22 eyes of 21 patients with active toxoplasma retino-choroiditis in zone -1 posterior pole  
  and peri-papillary areas were included in the study. One patient developed active lesion in the  
  fellow eye after 6 months which regressed after re-institution of the treatment.  
There were 11 females and 10 males. Age varied between 18-52 (mean age 29+8.8) years. The 
follow-up period varied between 4- 46 (mean 15+ 11) months. All patients showed resolution of 
retino-choroiditis and  improvement of visual acuity between 1- 9 lines (mean 4.18 lines+ 2.3).The 
mean lesion size pre-treatment was 0.89 disc diameters+0.3 and post-treatment was 0.70 disc 
diameters+0.28. The mean time taken for the sharpening of lesion borders was 2.3+0.4 (range 2-3) 
weeks. No complications reported with the medication. 
Conclusion 
The combination of trimethoprim-sulfamethoxazole and prednisolone is quite effective in 
treating the patients with active vision threatening posterior pole and peri-papillary 
toxoplasmosis lesions. 
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Introduction 
 
cular toxoplasmosis is the most 
common cause of posterior uveitis 
world over 1,2.  The retino – choroiditis is as 
a result of actively proliferating organisms  
which can destroy the retinal tissue with 
resultant retinal scars which can affect the 
visual acuity irreversibly3, 4. Hence the goal 
of treatment should be to arrest the 
multiplication of the parasite in the active 
stage at the shortest possible time and 
thereby decreasing the risk for vision loss.  
 There are multiple treatment options 
available including the more commonly 
used traditional combination therapy with 
pyrimethamine, sulfadiazine and folinic 
acid rescue5. The other drugs being 
tetracyclines, clindamycin, spiramycin, 
atovaquone, azithromycine, trovafloxacine  
and  trimethoprim-sulfamethoxazole.  
A combination of sulfadiazine with 
pyrimethamine and corticosteroids is 
considered the most effective treatment for 
toxoplasmosis; however the cost of 
treatment, significant side effects, non- 
availability in certain locations, the necessity 
for their combination and frequent dosing 
made them less compliant 5-7 pyrimethamine 
has depressant effect on bone marrow and 
needs folinic acid rescue to reverse it. These 
patients have to be followed with weekly 
laboratory blood tests.  
A less toxic means of treatment consists of 
clindamycin   in combination with 
sulfadiazine for 4 to 6 weeks 8. This 
combination was repeatedly shown to be 
effective in patients with ocular 
toxoplasmosis. Clindamycin has systemic 
side effects like skin rash, diarrhea and 
importantly psuedomembrane colitis which 
necessitate immediate interruption of 
clindamycin and institution of vancomycine 
or metronidazole therapy. Trimethoprim-
sulfamethoxazole has similar mechanism of 
action as pyrimethamine and sulfadiazine. 
In addition they were found to have similar 
efficacy in their inhibitory effect on T.gondii 
infected HeLa cells 9.  Trimethoprim- 
sulfamethoxazole is readily available as a 
fixed drug combination and has convenient  
BID dosing. The combination is time tested 
and proved to be safe. Unlike 
pyrimethamine which needs mandatory 
periodical hematological evaluation, it is not 
performed routinely during trimethoprim –
sulfamethoxazole therapy. In addition, it 
eliminates the need for folinic acid rescue 6,7. 
Rothova et al 6 used trimethoprim-
sulfamethoxazole for the first time in1989 in 
8 patients, as a part of their prospective 
multicentre study of ocular toxoplasma 
therapies. Opremcak et al 7 reported clinical 
efficacy of trimethoprim-sulfamethoxazole 
therapy in 16 patients. Since then this 
combination therapy has been used with 
increasing popularity such that the use of 
this therapy has increased from 5 % in 1992 
to 28 % in 20025, 10. 
 Recently 11 a major prospective randomized 
study has shown that the trimethoprim –
sulfamethoxazole and prednisolone therapy 
is an acceptable alternative to the standard 
therapy by sulfadiazine- pyrimethamine 
and prednisolone in treating ocular 
toxoplasmosis. All the studies 6,7,11 done so 
far were unclear about the efficacy of the 
combination therapy by trimethoprim-
sulfamethoxazole for the vision threatening 
posterior pole and peri-papillary lesions 
especially those that are involving fovea. 
Our aim was to review and evaluate our 
experience with fixed combination of 160mg 
trimethoprim and 800 mg sulfamethoxazole 
(Bacrim DS - Roche pharmaceuticals co.) 
and oral prednisolone in the patients with 
active zone-1 posterior retino - choroidal 
lesions threatening fovea and optic nerve. 
 
Materials and Methods 
 
The records of patients with active ocular 
toxoplasmosis in posterior pole and peri-
papillary areas, who received fixed 
combination antibiotics in our tertiary care 
referral hospitals (Magraby Eye Centre and 
King Abdul Aziz University Hospital) from 
January 2002 to May 2006, were analyzed 
retrospectively. The main outcome measures 
were clinical resolution of active retino-
choroiditis, visual out come and safety 
profile of the medication. All the patients 
underwent standard ocular evaluation 
including ocular and medical history; best 
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corrected visual acuity, slit lamp 
biomicroscopy and dilated fundus 
examination. The diagnosis of ocular 
toxoplasmosis was based on the clinical 
findings. All our cases had typical 
reactivation of congenital toxoplasma scars. 
However, Enzyme-linked immunosorbent 
assay (ELISA) was done for all the patients  
for Ig G and Ig M antibodies with undiluted 
serum. 
The active lesion of retino-choroiditis was 
documented in retinal diagrams in relation 
to macula and optic nerve. The patients 
were categorized according to the location 
of the lesion. The   lesions with in temporal 
arcades or 2 DD temporal to fovea and away 
from 500 microns of foveal centre  were 
considered as macular lesions. The lesions 
involving or with in 500 microns from 
foveal centre were considered as foveal 
lesions. The lesions with in 2 DD from optic 
nerve head were considered as Peri-
papillary lesions.  
 The activity was judged by the appearance 
of the lesion with respect to the pigmented 
scar, the color and the margin of the lesion, 
presence and absence of retinal 
hemorrhages, presence and absence of 
vitreous cells. The anterior vitreous 
inflammation was graded according to the 
standard system devised by Kimura et al.12 
The size of active lesion was measured 
clinically in disc diameters. The inactive 
adjacent scar was excluded in measurement. 
All these parameters were studied in 
subsequent follow-up visits i.e., 2 weeks, 3 
weeks, 4 weeks and 8 weeks. The time taken 
for the sharpening of lesion borders and 
resolution of vitreous inflammation noted.  
All patients were treated with 160 mg 
trimethoprime and 800 milligram of  
sulfamethoxazole, for a minimum period of 
4 weeks. The lesions affecting the foveal 
centre were treated for six weeks. 
Prednisolone tablets 1/2 mg  per kg body 
weight was given to all patients 48 hours 
after starting the first dose of 160 mg 
trimethoprime and 800 mg of 
sulfamethoxazole and tapered slowly for 2 
weeks for extra- foveal lesions and for 3 
weeks for foveal lesions. The patients who 
were allergic to sulfa were excluded. We did 
look for G6PD deficiency in our patients; 
however all of them were advised to 
observe the changes of urine color, and to 
report  to us immediately. 
Recurrence was defined as the active lesion 
as documented clinically after four weeks of 
inactivity. The patients with inadequate 
follow-up (i.e., less than 4 months) were 
excluded from the study. 
 
Results 
 
Retrospective study of records of the 
patients from our tertiary medical centers 
revealed a total of 38 patients with 
toxoplasma retino-choroiditis. Among them 
4 patients received clindamycin and were 
excluded from the study. Among the 
remaining 34 patients who received 
trimethoprim- sulfamethoxazole therapy, 11 
patients had extra macular lesions and 
hence excluded from the study. Among the 
remaining 23 patients 2 patients lost to 
follow-up after initial treatment. The 
remaining 21 patients with active 
toxoplasma retino-choroiditis lesions that 
were located in posterior pole and peri-
papillary areas were included for our study. 
One patient developed active foveal lesion 
in his fellow eye 6 months after institution 
of treatment however, showed regression of 
the lesion after re-institution of the 
treatment. Hence we analyzed 22 eyes of 21 
patients (Table 1). 
 All our patients had retinal scars. There 
were 11 females and 10 males. Age varied 
between 18-55 years.(mean 29.12+ 8.8 years). 
The Macular lesions and  Peri-papillary 
lesions were treated for 4 weeks. The Foveal 
lesions were treated for 6 weeks. The follow-
up period varied between 4- 46 months 
(mean 15 + 11 months) . There were 12 eyes 
with  macular lesions, 6 eyes with foveal 
lesions and 4 eyes  with nasal peri-papillary 
lesions. (Figure 1). All the foveal lesions 
were encroachments from the parafoveal 
lesions (macular) and none involved the 
foveal centre. 
All patients showed resolution of retino- 
choroiditis resulting in inactive scars. The 
time taken for the lesions to show 
sharpening of borders ranged from 2 to 3 
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Table 1. Details of patients’ characteristics, pre & post treatment (Pre / Post) visual acuity and 
lesion size, time taken for the sharpening of lesion border (T-sharp of LB) and follow-up. 
 
 
 
 
 
 
 
No Age Sex Eye  
 
 
 
 
Pre 
lesion 
Size 
(DD) VA pre 
 
 
 
 
 
 
Location 
Of lesion 
VA 
Post 
 
 
 
 
Post  
lesion 
Size 
(DD) 
 
 
 
 
 
T-sharp 
LB 
(weeks) 
 
Follow 
up 
period 
(month) 
 
1 18 F OD  
 
0.5 20/30 
 
Peripapillary 20/20 
 
0.5 
 
2 11 
2 22 M OS  1 20/60 Macular 20/20 0.6 2 9 
3 27 F OD  1.2 20/800 Macular 20/80 1.0 3 9 
4 32 F OD  1.2 20/100 Macular 20/20 1.0 3 11 
5 25 M OS  1.0 20/100 Macular 20/25 0.8 2 12 
6 35 M OD  1.0 20/600 Foveal 20/120 0.8 2 9 
7 42 F OD  0.8 20/60 Macular 20/20 0.6 2 9 
8 36 M OD  0.6 20/30 Macular 20/20 0.6 2 8 
9 25 M OS  1.2 20/120 Macular 20/60 1.0 2 8 
 
10 50 F OD 
 
 
0.5 
 
20/100 
 
Macular 20/30 
 
0.5 
 
2 
 42 
 
11 24 F OS  
 
0.5 20/25 
 
Peripaillary 20/20 
 
0.4 
 
2 36 
 
 
12 26 F OD 
 
 
 
0.5 
 20/100 
 
Macular 
 
20/60 
 
 
0.5 
 
 
2 
 46 
13 23 F OD  0.5 20/30 Peripapillary 20/20 0.4 2 10 
14 22 M OS  1.5 20/800 Foveal 20/600 1.6 3 12 
15 38 M OD  1.0 20/400 Foveal 20/100 0.6 2 18 
 
16 21 M  OD 
1.0 
20/600 
Foveal 
20/400 
0.7 2 
4 
 
16 21 M OU 
 
OS 
 
1.3 20/120 
 
Macular 
 
20/60 
 
1.0 
 
3 
 
10 
17 29 F OD  1.2 20/200 foveal 20/60 0.8 3 12 
18 33 M OS  1.0 20/40 Macular 20/20 0.6 2 14 
19 40 M OS  0.5 20/30 Peri-papillary 20/20 0.5 2 12 
20 52 F OS  0.8 20/80 Macular 20/20 0.4 3 14 
21 39 F OD  0.8 20/400 Foveal 20/100 0.6 3 14 
 
The established treatment for ocular 
toxoplasmosis has been the combination 
therapy with sulfadiazine and 
pyrimethamine for the past five decades13. 
The non availability of these combinations 
in certain locations, the frequent adverse 
reactions   and the need for their 
hematological monitoring has forced the 
clinicians to look for alternative drugs with 
almost equivalent efficacy and reliability5,7. 
Although, trimethoprim - sulfamethoxazole 
is therapeutically equivalent to sulfadiazine 
–pyrimethamine, clinically it was speculated 
to be inferior. 6 The use of these agents in 
 
treating vision threatening posterior pole 
and peri-papillary lesions without 
adjunctive treatment was never established. 
Rothova et al 6 used trimethoprim-
sulfamethoxazole for the first time in 8 
patients. Opremcak et al 7 used the fixed 
dose of the trimethoprim-sulfamethoxazole 
combination therapy in treating 
toxoplasmosis retino-choroiditis lesions. 
They categorized the patients according to 
location of lesions as described by Holland 
et al14. Zone-1 lesions were considered as the 
lesions located with in temporal arcades (2 
disc diameters from the fovea)
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or 2 disc diameters nasally from the optic 
nerve head. Zone 2 lesions are the lesions 
anterior to zone 1 and within clinical 
equator demarcated by anterior borders of 
vortex veins ampullae. Zone 3 lesions are 
anterior to zone 2 till ora serrata. The 
patients with zone 1 lesions and the other 
lesions with severe inflammation and 
opacified vitreous were treated with fixed 
dose combination of trimethoprim and 
sulfamethoxazole along with adjunctive 
therapy with clindamycin and oral 
prednisolone .The other zone 2 and 3 lesions 
did not receive the adjunctive treatment. 
The Zone 1 lesions received adjunctive 
therapy because they were adjacent to 
macula and optic nerve. Opremcak et al 
were unclear about the efficacy of the 
trimethoprim-sulfamethoxazole alone in 
treating these lesions. 
Recently Sohelian et al 11 in a major 
prospective randomized study comparing 
standard therapy with sulfadiazine-
pyrimethamine to the trimethoprim-
sulfamethoxazole therapy concluded that 
drug efficacies in terms of reduction in 
retinal lesion size and improvement in VA 
were similar in both regimens. However, 
they excluded the lesions involving 500 
microns with in fovea. Hence the role of 
trimethoprim-sulfamethoxazole in treating 
these critical lesions has not been studied. 
In our study, we attempted to treat the 
posterior pole and peri-papillary lesions 
with the trimethoprim-sulfamethoxazole 
therapy along with oral prednisolone. We 
followed our patiently more closely i.e., 2 
weeks , 3 weeks ,4 weeks and 6 weeks . All 
our patients showed resolution of the active 
disease without any adverse effects and 
recurrences.  
The treatment of toxoplasma induced retino 
- choroiditis is aimed to decrease the size of 
inflammatory mass and hence to limit the 
resulting the retino-choroidal scar. Sohelian 
et al 11 noted a mean reduction of 59% in the 
retinal lesion size which was similar (61%) 
to pyrimethamine - sulfadiazine therapy. 
Rothova et al 6 noted significant reduction of 
retinal lesion (defined as at least half a disc 
diameter reduction in diameter) in 11 % of 
patients receiving the trimethoprime-
sulfamethoxazole treatment which was 
significantly less than the response with 
pyrimethamine-sulfadiazine combination 
(49 %).  
Rothova et al 6 used trimethoprim – 
sulfamethoxazole in full dose (960- mg twice 
daily) for only 2 weeks. They used the half 
the dose (380 mg twice daily) for the 
remaining 2 weeks. In our study we used 
960 mg trimethoprim-sulfamethoxazole 
twice a day for 4 weeks. The patients with 
foveal zone disease received 6 weeks 
therapy. 
All the lesions were either stable (5 eyes ) or  
showed decrease  in size (16 eyes) of the 
active lesion during the treatment period 
except for one patient (pt.no.14) with 
Macular  disease (Figure 2) which showed 
mild increase to involve the foveal zone 
however showed regression after 
prolongation of treatment duration to 6 
weeks. The mean pre-treatment size of 
active lesions was 0.89 + 0.32 DD (range 0.5 
to 1.5 DD ) and post - treatment was 0.7 + 
0.28 DD (range 0.4 to 1.6 DD ). We measured 
the size of active lesion in disc diameters 
excluding the surrounding inactive scars.  
The authors did not calculate the percentage 
reduction of the lesions size as we believe in 
suggestion of  Holland15 that the time taken 
for the sharpening of lesion borders along 
with resolution of vitreous inflammation are 
far better indicator of the efficiency of 
treatment modality than the percentage 
decrease of retinal inflammatory lesion size 
as it ultimately leads to retinal scar. In our 
study, the average time for the sharpening 
of lesion border was 2.3 + 0.47 (range 2-3) 
weeks. The time required for a retino-
choroidal lesion to heal varies depending 
upon the size of the lesion, the treatment 
modality and the immunological condition 
of the host and the strain6,16,17. In our study  
the larger lesions > 1.0 DD took more time  
(3 weeks) to show sharpening of lesion 
border than the small lesions ( < 1.0 DD).  
Sohelian et al 11  noted  56.7 % of the patients 
showing improvement of vitreous 
inflammation after treatment with 
trimethoprim-sulfamethoxazole which was 
similar to the treatment with classic 
pyrimethamine-sulfamethoxazole therapy 
Trimethoprim, Sulfamethoxazole and Prednisolone for ocular toxoplasmosis 
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(69%). However, they have not mentioned 
the time taken for the resolution of the 
inflammation (trace to absence cells). In our 
study the eyes with smaller lesions were 
also the eyes which became quieter earlier 
than the eyes with larger lesions. 15 (68%) 
eyes  showed improvement of anterior 
vitreous inflammation with in 2 weeks and 
the remaining 7 (32 % ) eyes  took 3 weeks to 
show trace/absence of cells. The time taken 
for resolution of vitreous inflammation 
corresponded with time taken for the 
sharpening of lesion border and both 
depended upon the initial size of the lesion. 
As we mentioned earlier, the time taken for 
sharpening of lesion border and resolution 
of vitreous inflammation are better 
indicators of the efficacy of treatment. 
Sohelian et al 11 reported five lines 
improvement of snellens lines with 
trimethoprim-sulfamethoxazole therapy 
which was similar to that of pyrimethamine-
sulfamethoxazole therapy (5.5 lines.) 
Similarly Opremack et al 7 showed 
improvement of 5.2 lines in their patients. In 
our study, we noted 4.1 lines of 
improvement of visual acuity. This can be 
explained by the fact that all our patients 
had vision threatening macular and peri-
papillary lesions and 6 patients with foveal 
lesions. The vision improved in all patients 
including those who had foveal lesions. We 
speculate that the chemo-reduction of active 
lesion could have resulted in a much smaller 
scar sparing the surrounding zone of 
photoreceptors. However, there is no study 
supporting this hypothesis 
The great majority (80- 90 %) of ocular 
toxoplasmosis was believed to occur as a 
consequence of reactivation of congenitally 
acquired infection. An isolated and solitary 
and active lesion without previous retinal 
scars was considered as acquired infection15. 
A study from Iran 11 noted 50.8 % of their 
patients without retinal scars suggesting of 
having had acquired infection. Furthermore, 
they observed that these patients with 
acquired disease were showing better 
response to pyrimethamine-sulfadiazine 
therapy than with the Trimethoprim - 
sulfamethoxazole. In our study all our 
patients had retinal scars and hence had 
congenital infection and showed good 
response by the use of trimethoprime-
sulfamethoxazole.  The congenital ocular 
toxoplasmosis may be more effectively 
treatable with the use of trimethoprim-
sulfamethoxazole than acquired disease. 
This needs to be confirmed by further study. 
 As all the available drugs including the 
trimethoprim-sulfamethoxazole regime, are 
incapable of eradicating the latent tissue 
cysts, recurrences were observed with all 
treatment modalities 17. Opremcak et al 7 
encountered 3 recurrences in one patient. 
Sohelian et al12 noted 3 recurrences in the 
trimethoprime and sulfamethoxazole 
treatment group and similar recurrences 
with sulfadiazine-pyrimethamine therapy. 
We did not encounter recurrences in any of 
treated eyes during our follow up period 
that ranged from 4 to 46 months. In view of 
our limited follow-up we are unable to 
comment on the recurrences. 
The Medline search did not reveal 
occurrence of simultaneous bilateral active 
toxoplasmosis lesions in immuno-competent 
persons. Moshfegi et al18 noted atypical 
widespread active bilateral toxoplasmic 
retinochoroidits in a HIV patient. How ever 
there is a possibility of fellow eye getting 
active disease during follow up as happened 
to one of our patient  No 16 (Table 1) who 
developed active foveal lesion  in the fellow 
eye (OD)  6 months after the institution of 
trimethoprim-sulfamethoxazole therapy. 
This patient showed regression of the lesion 
after re-institution of the trimethoprim-
sulfamethoxazole therapy. This may be 
considered as recurrence of the disease in 
the fellow eye considering the systemic 
nature of the therapy. 
The trimethoprim and sulfamethoxazole 
combination therapy has been used for 
prophylaxis against toxoplasma induced  
encephalitis in AIDS patients in 1992 19. The 
long term intermittent trimethoprim- 
sulfamethoxazole treatment was shown to 
prevent the recurrences in ocular 
toxoplasmosis 20.    
Opremcak et al 7 noted mild rash, colitis and 
headache in 2 patients each. Sohelian et al 11 
noted mild rash in one patient. All our 
patients did not complain any of these 
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adverse events. This suggests well 
tolerability of this combination in our part of 
the world. 
 The systemic corticosteroids are necessary 
to contain the necrotizing inflammatory 
process which can damage the visually 
sensitive areas like macula and optic nerve. 
The treatment with steroids is usually 
delayed by 12 - 48 hours after institution of 
anti-toxoplasma treatment to achieve 
therapeutic levels of the drug and usually 
tapered 2 weeks before the discontinuation 
of the treatment. All our patients received 
oral prednisolone (1/2 mg per kg body 
weight) 48 hours after the institution of 
initial dose and slowly tapered for 2 weeks 
for extra- foveal lesions and tapered for 3 
weeks for foveal lesions. We did not use the 
higher dose of steroids as we wanted the 
anti- inflammatory effect only. In addition to 
contain inflammatory mass size the 
corticosteroids also aid in reducing the 
accompanying vitritis, cystoid macular 
edema and the retinal vasculitis. 
Active toxoplasma retinochoroiditis is a self 
limited disease for which there is inadequate 
evidence to support the routine use of 
antibiotics21.   How ever, considering the 
consequences of irreversible loss of vision 
by untreated active posterior lesions 
especially involving fovea and optic nerve 
and the suggestive evidence that the 
treatment can reduce the resultant retinal 
scar6, it seems reasonable to treat the active 
toxoplasmosis lesions  with safe and 
effective medication with the least side 
effects. 
The results of our study show that 
trimethoprim - sulfamethoxazole therapy 
along with oral corticosteroids appears to be 
effective and sufficient in treating ocular 
toxoplasmosis even in vision threatening 
lesions. This may obviates the need for other 
adjunctive drugs like clindamycin, thus 
lessening the cost, minimizing the adverse 
effects and improving patient compliance. 
How ever, there is a need for a prospective, 
randomized control study to test the 
efficiency of combined use of trimethoprim - 
sulfamethoxazole therapy in treating the 
vision threatening posterior pole and peri-
papillary lesions with respect to the natural 
course of untreated disease and with respect 
to established treatment modalities with 
drugs such as sulfadiazine-pyrimethamine 
and clindamycin. 
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